Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.

Leukemia research - 1 Jun 2009

Sanchez-Guijo Fermin M, Lopez-Jimenez Javier, Gonzalez Tomas, Santamaría Carlos, González Marcos, Del Cañizo Maria-Consuelo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Combined Modality Therapy
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 19038446
DOI: 10.1016/j.leukres.2008.10.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.PMID 19038446Read ↗

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.Semantic proximity Read ↗

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Semantic proximity Read ↗

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.Semantic proximity Read ↗

Update on rational targeted therapy in AMLSemantic proximity Read ↗

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCTSemantic proximity Read ↗

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Haematological cancer: Ponatinib in CML - keeping PACE with multiple mutations.Semantic proximity Read ↗

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceSemantic proximity Read ↗

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.Semantic proximity Read ↗

TP-0903 is active in models of drug-resistant acute myeloid leukemia.Semantic proximity Read ↗

Targeted therapy of chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.